NeoGenomics, Inc. Expands Oncology Testing Portfolio Access Through Epic Aura Integration

Published: 2026-04-23 09:21:48 ET NEO

Published on 04/23/2026 at 09:21 am EDT

NeoGenomics, Inc. announced that its oncology testing portfolio is now available through Epic Aura, enabling seamless access to oncologists and health systems across the United States through the Epic electronic health record workflow. Through this integration, physicians can order NeoGenomics? comprehensive suite of tests, spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care.

This streamlined approach lowers barriers to entry for hospitals and health systems, enhances the scalability of NeoGenomics? testing capabilities, and could drive 20-30% increase in test adoption per site, supporting faster time to treatment for patients facing a cancer diagnosis. This integration represents a significant step forward in NeoGenomics?

digital health strategy, strengthening connectivity across community oncology practices and large health systems. This scalable, ?build once, deploy broadly? infrastructure will support the delivery of next-generation diagnostic capabilities, including liquid biopsy and molecular residual disease.